Growth hormone (GH) stimulates growth and metabolism but also displays profound effects on the central nervous system (CNS). GH affects neurogenesis and neuroprotection, and has been shown to counteract drug-induced apoptosis in the brain. Anabolic androgenic steroids (AAS), mainly abused for their anabolic and performance-enhancing properties, can cause several adverse effects, such as cardiovascular complications, sterility, depression, and aggression. GH and AAS are both believed to interact with several signaling systems in the CNS. The aim of this thesis was to further investigate the impact of GH and AAS on neurochemistry and cognitive functions. Recombinant human GH (rhGH) and the steroid nandrolone decanoate (ND) were administered, separately and in combination with each other, to male rats. The results demonstrated that administration of GH improved spatial memory, assessed in a water maze test. Furthermore, GH induced alterations of the GABAB receptor mRNA expression, density, and functionality in the brain, for example in regions associated with cognition. GH also altered the mu opioid peptide (MOP) receptor, but not the delta opioid peptide (DOP) receptor functionality in the brain. Thus, some of the GH effects on cognition may involve effects on the GABAB receptors and MOP receptors. ND, on the contrary, seemed to induce impairments of memory and also altered the GABAB receptor mRNA expression in the brain. Furthermore, ND lowered the IGF-1 plasma concentrations and attenuated the IGF-1, IGF-2, and GHR mRNA expression in the pituitary. In addition, significant effects of GH and ND were found on plasma steroid concentrations, organ weight, as well as body weight. In conclusion, this thesis contributes with further knowledge on the cognitive and neurochemical consequences of GH and ND use. The findings regarding ND are worrying considering the common use of AAS among adolescents. GH improves memory functions and affects signaling systems in the brain associated with cognition, hence the hypothesis that GH can reverse drug-induced impairments is further strengthened.

O uso de esteróide anabolizante é cada vez maior por pessoas que praticam exercícios como forma de lazer, sem se importarem com os possíveis efeitos colaterais, o que vem se tornando um importante problema de saúde pública. Dentre os seus principais efeitos colaterais, destacamos a hipertrofia cardíaca, que parece ser ainda mais pronunciada quando associado ao treinamento físico, sendo esta relacionada a maior atividade da enzima conversora de angiotensina cardíaca. Tendo em vista esse cenário, o presente trabalho visa verificar a participação do sistema renina angiotensina aldosterona sobre a hipertrofia cardíaca e síntese de colágeno induzida pelo esteróide anabolizante, associado ao treinamento físico por natação em ratos, por meio do bloqueio de receptores AT1 com Losartan e dos receptores de mineralocorticóides com Espironolactona. Resultados mostram que a administração de esteróide anabolizante aumenta a ativação do sistema renina angiotensina aldosterona cardíaco, o qual está diretamente relacionado aos seus efeitos colaterais, visto que o bloqueio dos receptores AT1 ou dos RM inibiu esses efeitos. Sendo mostrado pela primeira vez, os efeitos do esteróide anabolizante sobre o aumento na expressão do gene da aldosterona sintase e da enzima 11-HSD2, sugerindo os efeitos dos esteróides anabolizantes sobre o aumento da síntese e atividade da aldosterona cardíaca / The anabolic steroid use is growing by recreational exercise practitioners, without worried about the possible collateral effects, becoming an important problem of public health. Among its deleterious effects we detach the cardiac hypertrophy, that looks to be still bigger when the swimming training was associated, being is related to bigger activity of the cardiac angiotensin converter enzime. With that, the present work is going to verify the renin angiotensin aldosteron system participation about the cardiac hypertrophy and collagen synthesis prompted by the anabolic steroid and the association with the swimming training in rat by means of the AT1 receivers blockade with Losartan and of the mineralocorticoids receivers blockade with Espironolacton. Our results show that the anabolic steroid administration increased the cardiac rennin angiotensin aldosteron system activity, that is straightly related to its deleterious effects, seen that the AT1 receivers blockade or the mineracorticoids receivers blockade inhibited those effects. Being shown by the first time the anabolic steroids effects about the increase of the aldosterone sintase gene expression and of the 11-HSD2 enzyme, suggesting the anabolic steroids effects about the cardiac aldosterone synthesis and activity increase

Introdução: Os esteroides androgênicos anabolizantes (EAA) são hormônios sintéticos análogos à testosterona, utilizados em homens para tratar o hipogonadismo. Sabendo dos potenciais efeitos tróficos na musculatura esquelética, muitos atletas e frequentadores de academia começaram a autoadministrar estes ergogênicos de forma ilícita e abusiva. Segundo a literatura, o uso abusivo interfere diretamente no sistema nervoso central, com aumento exacerbado da atividade nervosa simpática muscular (ANSM) associado à uma redução do fluxo sanguíneo muscular (FSM) periférico em repouso. Porém, não é conhecido o comportamento reflexo da ANSM e FSM pelo estímulo mecano/metaborreflexo (exercício isométrico) e do comando central (estresse mental) em jovens usuários de EAA. Objetivos: Testar a hipótese de que indivíduos que fazem uso de EAA, apresentam exacerbação da resposta da ANSM e redução do FSM pela via aferente mecanorreflexa e metaborreflexa, bem como, pela via eferente do comando central. Métodos: Foram selecionados 37 voluntários praticantes de treinamento resistido (musculação) por pelo menos 2 anos. Dezenove usuários de EAA (UEAA) por pelo menos 2 anos e 18 não usuários (NUEAA) foram incluídos no estudo. Todos os participantes realizaram anamnese, coleta de urina para análise toxicológica e avaliação da composição corporal por meio da absorciometria de raio-X de dupla energia (DXA). A ANSM foi avaliada pela técnica de microneurografia. O FSM do antebraço foi avaliado pelo método de pletismografia de oclusão venosa. A pressão arterial foi avaliada de forma não invasiva, batimento-a-batimento cardíaco, pelo método oscilométrico (Finometer®) e a frequência cardíaca (FC) foi registrada pelo eletrocardiograma. O estímulo mecano/metaborreflexo foi testado pelo exercício isométrico (preensão de mão) a 30% da contração voluntária máxima durante 3 minutos. O estímulo do comando central foi testado pelo estresse mental (Stroop Color Word Test) durante 4 minutos. Resultados: O grupo UEAA apresentou maior peso corporal (90,7±12,0 vs. 81,0±12,5 kg, respectivamente; p=0,02), índice de massa corporal (29,1± 2,8 vs. 25,3±2,2 kg/m2, respectivamente; p < 0,001) e massa magra (78,1±7,6 vs. 63,0±7,3 kg, respectivamente; p<0,001) quando comparado ao grupo NUEAA. No período basal, observamos maior ANSM (23±6 vs. 15±4 disparos/min; p < 0,001), ANSM/100 batimentos cardíaco (34±9 vs. 24±6 disparos/100bat; p=0,001) e FC (69±6 vs. 61±6 bpm; p < 0,001) no grupo UEAA quando comparado ao NUEAA. Para as demais variáveis hemodinâmicas e neurovasculares no período basal, não foram observadas diferenças significativas. Durante o exercício isométrico, a resposta pico do 3º min da FC (84±8 vs. 76±11bpm; p < 0,05) e PAM (122±14 vs. 113±11 mmHg; p < 0,05) foram maiores no grupo UEAA quando comparado ao NUEAA, entretanto, não houve diferença na resposta da ANSM, ANSM/100bat, FSM e CVA entre os grupos. Durante o estresse mental, a resposta pico do 4º min da ANSM (31±3 vs. 24 ± 5 disparos/min; p < 0,01) e da FC (76±7 vs. 69±10 bpm; p=0,01) foi maior no grupo UEAA quando comparado ao NUEAA. A resposta pico do FSM (3,08±1,16 vs. 4,34±1,57 ml/min/100ml; p < 0,01) e da CVA (3,00±1,29 vs. 4,21±1,25 ml/min/100ml; p < 0,01) foi menor no grupo UEAA quando comparado ao grupo NUEAA. Não houve diferença na resposta da ANSM/100bat entre os grupos. Conclusão: Durante a estimulação mantida de mecano-metaborreceptores, os UEAA apresentaram respostas semelhantes da ANSM, FSM e CVA. No entanto, durante a estimulação do comando central, os UEAA apresentaram ANSM exacerbada e atenuação da resposta vasodilatadora muscular. Dessa forma, o comando central parece ser uma importante via de ativação neural que desencadeia a disfunção vasodilatadora muscular observada em UEAA em situações reacionais de estresse / Introduction: Anabolic androgenic steroids (AAS) are synthetic hormones analogous to testosterone used to treat hypogonadism in men. Assuming the potential trophic effects on skeletal muscle, many athletes have used these illicit drugs abusively. According to the literature, AAS abuse directly interferes with the central nervous system, with an exacerbated increase in muscle sympathetic nerve activity (MSNA) associated with a reduction in forearm blood flow (FBF). However, the reflex response of MSNA and FBF by the mechano/metaboreflex stimulus (isometric exercise) and the central command (mental stress) in young AAS users have never been tested. Objective: To test the hypothesis that AAS abuse would cause an exacerbated MSNA associated with reduced FBF by increasing afferent mecanorreflex and metaboreflex activation and efferent central command response. Methods: We enrolled 37 participants who have been practicing resistance training for at least 2 years. Nineteen AAS users self-administering AAS for at least 2 years (AASU) aged 31±6 yr and eighteen AAS nonusers (AASNU) aged 29±4 yr were included. All participants underwent anamnesis, urine collection for toxicological analysis and body composition assessment using dual energy X-ray absorptiometry (DXA). MSNA was evaluated by microneurography technique and FBF was evaluated by venous occlusion plethysmography. Blood pressure was evaluated non-invasively, beat-by-beat by oscillometric method (Finometer®) and heart rate (HR) was recorded by electrocardiogram. The mechano/metaboreflex stimulus was tested by isometric exercise (handgrip) at 30% of maximal voluntary contraction for 3 minutes. The central command stimulus was tested by mental stress (Stroop color-word test) for 4 minutes. Results: AASU had higher body weight (90.7±12.0 vs. 81.0 ± 12.5 kg, respectively, p = 0.02), body mass index (29.1 ± 2.8 vs. 25.3 ± 2.2 kg/m2, respectively, p < 0.001) and lean mass (78.1 ± 7.6 vs. 63.0 ± 7.3 kg, respectively, p < 0.001) when compared with AASNU. At baseline, we observed higher MSNA (23 ± 6 vs. 15 ± 4 burts / min, p < 0.001), MSNA / 100 beats (34 ± 9 vs. 24 ± 6 burts / 100 beats, p = 0.001) and HR (69 ± 6 vs. 61 ± 6 beats/min, p < 0.001) in AASU compared with AASNU. There were no significant differences for hemodynamic and neurovascular variables at baseline. During isometric exercise, peak HR response at 3rd min (84 ± 8 vs. 76 ± 11bpm, p < 0.05) and median arterial blood pressure (122 ± 14 vs. 113 ± 11 mmHg, p < 0.05) were higher in AASU when compared with AASNU. There were no differences in MSNA response, MSNA / 100 beats, FBF and FVC between groups. During mental stress, peak MSNA response at 4th min (31 ± 3 vs. 24 ± 5 bursts / min, p < 0.01) and HR (76 ± 7 vs. 69 ± 10 beats/ min, p = 0,01) was higher in AASU when compared with AASNU. Peak FBF (3.08 ± 1.16 vs. 4.34 ± 1.57 ml / min / 100 ml, p < 0.01) and FVC responses (3.00 ± 1.29 vs. 4.21 ± 1.25 ml / min / 100 ml, p < 0.01) were lower in AASU compared with AASNU. There was no difference in MSNA / 100 beats response between groups. Conclusions: During sustained mechano-metaboreceptors stimulation, AASU presented similar MSNA, FBF and FVC responses. However, during central command stimulation, AASU presented exacerbated MSNA and blunted FBF. Thus, the central command seems to be an important neural activation pathway that triggers the muscular vasodilator dysfunction observed in AASU in reactive stress situations

Despite numerous studies have demonstrated an association of type 2 diabetes mellitus (T2DM) and osteoporosis, the underlying mechanism connecting these two conditions remains elusive. Clinically, combined calcium and vitamin D supplement is the commonest osteoporosis therapy; however, recent studies have suggested an increase in cardiovascular risks associated with calcium plus vitamin D supplementation. Therefore, an alternative strategy in treating osteoporosis patients with T2DM is urgently needed. In this study, we hypothesized that combined administration of menaquinone-4 (vitamin K₂, biologically active form of vitamin K) and 1α,25-dihydroxyvitamin D₃ (vitamin D₃, biologically active form of vitamin D) as a novel therapy in treating osteoporosis of T2DM patients. Anabolic effect of vitamin K₂ and vitamin D₃, alone or in combination, was assessed on primary osteoblasts harvested from the iliac crests of C57BL/KsJ lean (db⁺/m⁺) and obese/diabetic (db⁺/db⁺, leptin receptor-deficient) mice. Furthermore, the underlying cellular mechanism was also investigated. Serum undercarboxylated osteocalcin (an indication of vitamin K₂ level) level was higher whereas vitamin D₃ level was lower in db⁺/db⁺ mice, and sections of the iliac crests of db⁺/db⁺ mice illustrated extensive porous structures filled with enlarged adipocytes compared with db⁺/m⁺ mice. Lower levels of bone anabolic markers and bone formation transcription factors (osteocalcin, Runx2, Dlx5, ATF4, type I collagen, OSX, alkaline phosphatase (ALP) activity, p-Smad1/5/8 and p-ERK1/2) were observed in the osteoblasts of db⁺/db⁺ mice. Acute vitamin D₃ (10 nM) application elicited a more sustained and greater magnitude of increase of [Ca²⁺]ᵢ in osteoblasts of db⁺/m⁺ mice when compared with db⁺/db⁺ mice. A significantly higher level of calcium deposits in osteoblasts was observed in db⁺/m⁺ mice when compared to db⁺/db⁺ mice. Co-administration of vitamin K₂ (10 nM) and vitamin D₃ (10 nM) caused an enhancement of calcium deposits in osteoblasts in both strains of mice. Vitamins K₂ and D₃ co-administration time-dependently (7, 14 and 21 days) increased the levels of bone anabolic markers and transcription factors for bone formation, with a greater magnitude of increase observed in osteoblasts of db⁺/db⁺ mice. Suppressed expression of calcium-sensing receptor (CaSR), F-actin, V-ATPase, vitamin D receptor (VDR) and pregnane X receptor (PXR) observed in osteoblasts of db⁺/db⁺ mice were partially reversed by combined vitamins treatment. Moreover, combined vitamins K₂ plus D₃ treatment significantly enhanced migration and the appearance of surface microvilli and ruffles of osteoblasts of db⁺/db⁺ mice. Effects of combined vitamins K₂ plus D₃ treatment observed in osteoblasts of db⁺/db⁺ and db⁺/m⁺ mice were eradicated by warfarin (20 µM, a vitamin K epoxide reductase inhibitor). Thus, our results illustrate that vitamins K₂ plus D₃ supplementation is a novel therapeutic strategy in treating osteoporosis of T2DM patients. / 儘管大量研究已證明第二類型糖尿病和骨質疏鬆症的關聯，連接這兩個病症的基本機制仍然是難以捉摸的。在臨床上，鈣和維生素D的綜合補充劑是最常見的骨質疏鬆症治療，然而最近的研究卻表明服用鈣和維生素D的綜合補充劑會增加患者的心血管風險，因此急切需要尋找可以給予同時患有骨質疏鬆症和第二類型糖尿病患者的替代治療。在本研究中，我們假設甲萘醌-4（維生素K₂，維生素K生物活性形式）和1α，25 - 二羥基維生素D₃（維生素D₃，維生素D的生物活性形式）可以嘗試在同時患有骨質疏鬆症和第二類型糖尿病患者身上作為一種革新的療法。本研究從C57BL/KsJ瘦削/非糖尿病 (db⁺/m⁺) 的小鼠和肥胖/帶有第二類型糖尿病基因 (db⁺/db⁺) 兼有瘦素受體缺陷的小鼠的髂嵴原始成骨細胞上對維生素K₂和維生素D₃單獨或組合使用的合成代謝作用進行了評估。此外，我們也對該成骨細胞的底層機制進行了一系列的研究。 / 在肥胖/帶有第二類型糖尿病基因的小鼠血清內低羧骨鈣素水平（維生素K₂水平的指標）較高而維生素D水平較低，另外，它們的髂嵴的部分與瘦削/非糖尿病的小鼠相比，呈現出比較廣泛的多孔結構並填滿了擴大的脂肪細胞。從肥胖/帶有第二類型糖尿病基因的小鼠的成骨細胞中，可以觀察到它們的骨合成代謝的標誌物和骨骼形成的轉錄因子 (骨鈣蛋白，Runx2，Dlx5，ATF4，第一類型骨膠原，OSX，鹼性磷酸酶 (ALP) 活性，p-Smad1/5/8和p-ERK1/2) 的水平比較低。急性維生素D₃ (10 nM) 的應用在瘦削/非糖尿病小鼠的成骨細胞比起在肥胖/帶有第二類型糖尿病基因的小鼠的成骨細胞引起更持續和更大幅度的細胞內鈣變化增加。在瘦削/非糖尿病小鼠的成骨細胞中比起在肥胖/帶有第二類型糖尿病基因的小鼠的成骨細胞有顯著較高的鈣沉積形成。維生素K₂ (10 nM) 和維生素D₃ (10 nM) 的綜合藥在兩種小鼠的成骨細胞中可以有效地增強鈣沉積的形成。維生素K₂和維生素D₃的綜合藥對增加骨合成代謝的標誌物和骨形成轉錄因子的水平有時間依賴性 (7，14和21日)，療程越長至21日，在肥胖/帶有第二類型糖尿病基因小鼠的成骨細胞中有更大的幅度的增加。合併維生素治療能部分有效地逆轉在肥胖/帶有第二類型糖尿病基因小鼠的成骨細胞中被抑制表達的鈣敏感受體 (CASR)，F-肌動蛋白，V-ATP酶，維生素D受體 (VDR) 和孕烷X受體 (PXR)。此外，結合維生素K₂加維生素D₃治療顯著增強了肥胖/帶有第二類型糖尿病基因小鼠的成骨細胞的細胞遷移和增加了成骨細胞表面外觀的微絨毛和褶皺。在瘦削/非糖尿病小鼠的成骨細胞及肥胖/帶有第二類型糖尿病基因的小鼠的成骨細胞上結合維生素K₂加維生素D₃的治療效果被華法林 (20 μM，維生素K環氧化物還原酶抑製劑) 根除。因此，我們的結果証明了維生素K₂加維生素D₃補充劑的結合使用可有效地作為治療第二類型糖尿病患者並患有骨質疏鬆症的一種新的治療策略。 / Poon, Chui Wa Christina. / Thesis (Ph.D.)--Chinese University of Hong Kong, 2014.n5203 / Includes bibliographical references (leaves 135-151). / Abstracts also in Chinese. / Title from PDF title page (viewed on 26, October, 2016). / Detailed summary in vernacular field only. / Detailed summary in vernacular field only.

Os esteroides anabolizantes androgênicos (EAA) como o decanoato de nandrolona (ND) são hormônios sintéticos derivados da testosterona. Sabe-se que um dos efeitos mais marcantes da administração abusiva destes esteroides é o aumento do comportamento agressivo. Evidências indicam que altas doses de EAA alteram a morfologia e causam hiperativação de sinapses glutamatérgicas, o que se correlaciona com um fenótipo agressivo exacerbado. Fisiologicamente o glutamato é considerado o principal neurotransmissor excitatório no cérebro de mamíferos, entretanto, em níveis elevados, pode causar hiperexcitabilidade neuronal mediada pelos receptores glutamatérgicos ionotrópicos do tipo N-metil-d-aspartato (NMDAr) e, consequentemente alterações no metabolismo mitocondrial. A terminação da sinalização excitatória glutamatérgica é realizada majoritariamente por transportadores existentes em astrócitos. Neste sentido, o transportador astrocitário de glutamato GLT-1 é responsável por mais de 90% da remoção do glutamato da fenda sináptica, contribuindo significativamente, para a manutenção da homeostasis da sinalizacão glutamatérgica. A administração do antibiótico β-lactâmico ceftriaxona (CEF) aumenta a expressão de GLT-1 e diminui a hiperexcitabilidade glutamatérgica, o que poderia potencialmente contrapor mecanismos cerebrais associados ao aumento do fenótipo agressivo induzidos pelo decanoato de nandrolona (ND). Entretanto, estas possíveis interacões moleculares e comportamentais ainda não foram exploradas. Assim, o objetivo primário deste trabalho foi investigar se o aumento da expressão do transportador astrocitário GLT-1 modula mecanismos glutamatérgicos envolvidos na agressividade induzida pelo ND, e a atividade mitocondrial. Para tanto, camundongos CF-1 machos de 60 dias de idade foram divididos em 4 grupos: veículo oleoso (VEH), nandrolona (ND), ceftriaxona (CEF) e nandrolona+ceftriaxona (ND/CEF). A nandrolona foi injetada por via subcutânea (15mg/Kg) por 19 dias. A ceftriaxona (200mg/Kg) ou solução salina foram administradas intraperitonealmente por 5 dias. Após a última injeção foi avaliada a latência para o primeiro ataque e o número de ataques no teste do intruso. Os animais foram sacrificados logo após o teste, e homogeneizados de córtex foram utilizados para imunoquantificação do GLT-1 e da fosforilação da subunidade pNR2Bser1232 do NMDAr. A atividade mitocondrial foi avaliada em sinaptossoma de cérebro total. Os níveis de glutamato foram medidos no líquido cefalorraquidiano. Comparado com o veículo, o tratamento com ND diminuiu significativamente a expressão do GLT-1, aumentou os níveis de glutamato e a expressão da subnidade pNR2Bser1232 o que foi mecanisticamente associado ao aumento do fenótipo agressivo; diminuicão da latência e aumento do número de ataques ao intruso. Ainda, a ND diminuiu o controle respiratório mitocondrial. A administração de CEF aumentou significativamente a expressão do GLT-1 e diminuiu os níveis de glutamato em relação ao grupo ND, enquanto que os níveis de pNR2Bser1232 e a agressividade foram similar ao grupo controle. No grupo ND/CEF o immunoconteúdo de GLT-1 e de pNR2Bser1232, os níveis de glutamato e o fenótipo agressivo, foram significativamente menores que no grupo ND, e similares ao grupo controle. Ainda, a CEF foi capaz de atenuar o prejuízo no controle respiratório mitocondrial causado pela ND. Nossos resultados demonstram que a interação bidirecional entre o transportador astrocitário GLT-1 e a subunidade pNR2Bser1232 neuronal mediada pelo glutamato, exercem um impacto regulatório no fenótipo agressivo induzido pela ND, e no controle respiratório mitocondrial. Desta maneira, este modelo reforça a importância da homeostasia funcional da sinapse tripartide glutamatérgica no fenótipo agressivo. / Anabolic androgenic steroids (AAS) such as nandrolone decanoate (ND) are synthetic hormones derived from testosterone. It is known that one of the most important adverse effects of abusive administration of these steroids is the increase in aggressive behavior. Evidence indicates that high doses of AAS alter morphology and cause hyperactivation of glutamatergic synapses which correlates with an aggressive exacerbated phenotype. Physiologically, glutamate is considered the main excitatory neurotransmitter in the mammalian brain. At high glutamate levels, occurs neuronal hyperexcitability mainly trhough the ionotropic N-methyl-d-aspartate (NMDAr) type of glutamatergic receptors and, consequently, changes in mitochondrial metabolism. Existing transporters in astrocytes predominantly perform the termination of glutamatergic excitatory signaling. In this sense, the GLT-1 glutamate astrocytic transporter is responsible for more than 90% of glutamate removal from the synaptic cleft, contributing significantly to the maintenance of glutamatergic signaling homeostasis. Administration of the β-lactam antibiotic ceftriaxone (CEF) increases GLT-1 expression and decreases glutamatergic hyperexcitability, which could potentially counteract brain mechanisms associated to increased aggressive phenotype mediated by nandrolone decanoate (ND). However, a possible molecular and behavioral interaction has not yet been explored in context. Thus, the primary objective of this work was to investigate whether increased expression of the GLT-1 astrocyte transporter modulates the glutamatergic mechanisms involved in ND-induced aggressive phenotype, and mitochondrial activity. Sixty-day-old male CF-1 mice were divided into 4 groups: oil vehicle (VEH), nandrolone (ND), ceftriaxone (CEF) and nandrolone + ceftriaxone (ND / CEF). Nandrolone was injected subcutaneously (15mg / kg) for 19 days. Ceftriaxone (200mg / kg) or saline solution were administered intraperitoneally for 5 days. After the last injection, the latency for the first attack and the number of attacks on the intruder test were evaluated. The animals were sacrificed after the test, and homogeinized cortex were used for immunoquantification of GLT-1 and phosphorylation of the NMDAr pNR2Bser1232 subunit. Mitochondrial activity was evaluated in total brain sinaptossomes. Glutamate levels were measured in the cerebrospinal fluid. Compared to the vehicle group, treatment with ND significantly decreased the expression of GLT-1, increased glutamate levels and expression of the pNR2Bser1232 which was mechanistically associated with an increase in the aggressive phenotype; decrease in the latency and increase in the number of attacks. Also, ND decreased mitochondrial respiratory control. Administration of CEF significantly increased GLT-1 expression and decreased glutamate levels relative to the ND group, whereas pNR2Bser1232 levels and aggressive phenotype were similar to the control group. In the ND / CEF group the expression of GLT-1 and pNR2Bser1232, glutamate levels and aggressive phenotype were significantly lower than in the ND group, and similar to the control group. Furthermore, CEF was able to attenuate the alteration in the mitochondrial respiratory control caused by ND. Our results demonstrated that the levels of glutamate astrocytic transporter GLT-1 and pNR2Bser1232 are important mechanism behind the increased aggressive phenotype induced by ND, and decreased mitochondrial respiratory control. Also, this model reinforces the importance of glutamate levels and astrocytic molecular targets in the regulation of the aggressive phenotype.

Submitted by Celso Magalhaes (celsomagalhaes@ufrrj.br) on 2018-03-26T14:34:13Z No. of bitstreams: 1 2015 - Fernando de Azevedo da Cruz Seara.pdf: 1716878 bytes, checksum: 6a6ea74b23b441a8aafb15e937dea036 (MD5) / Made available in DSpace on 2018-03-26T14:34:14Z (GMT). No. of bitstreams: 1 2015 - Fernando de Azevedo da Cruz Seara.pdf: 1716878 bytes, checksum: 6a6ea74b23b441a8aafb15e937dea036 (MD5) Previous issue date: 2015-07-24 / Coordena??o de Aperfei?oamento de Pessoal de N?vel Superior - CAPES / According to World Health Organization, ischemia heart diseases are the leading cause of death worldwide. Among therapeutic approaches, reperfusion is the most effective and indicated is reperfusion. Despite the better post-infarction prognostic, absolute improvement on cardiac function is hardly achieved due to ischemia/reperfusion injury (IRI). Within this context, anabolic steroids (AS) administration, in adult Wistar rats, significantly increase IRI susceptibility. Moreover, chronic administration of AS, during adolescent phase, induces persistent cardiovascular dysfunctions along adulthood. Therefore, the aim of the present study was to analyze the effects of chronic administration of supraphysiologic doses of testosterone propionate, during adolescent phase, in the susceptibility to ischemia/reperfusion injury, in adult Wistar rats. To perform it, 24 Wistar rats were allocated into two groups, AS (Testosterone propionate 5 mg kg-1, since 26? day postnatal, 5 days per week, during 5 weeks) and Control (Vehicle). In the 82? postnatal, rats were euthanized and hearts, livers, lungs, kidneys and testicles were collected. Isolated hearts were artificially perfused with modified Krebs-Henseleit solution, through Langendorff apparatus, and, then, submitted to ex vivo ischemia ? reperfusion protocol (20 minutes of stabilization, 30 minutes of global ischemia and 60 minutes of reperfusion). The left ventricle (LV) end diastolic- LVEDP), systolic- (LVSP) and developed pressures (LVDP), as well as first derivatives of pressure, maximum and minimum (dP/dt, maximum and minimum, respectively) were measured through an intraventricular latex balloon, connected to a pressure transducer. Through the electrocardiogram, susceptibility to arrhythmic episodes was analyzed. At the end of the protocol, area of infarct was delimited and gene expression of ? and ? myosin heavy chains and Glyceraldehyde 3-phosphate dehydrogenase, as well as the activity of nicotinamide adenine dinucleotide phosphate-oxidase (Nox) enzymes, were calculated. In comparison to Control group, hearts from AS group presented: Hypertrophy, due to an increase in cardiac mass (33%, P<0,001) and index (37%, P<0,001); Significantly increase in the area of infarct (54,76%, P<0,05); Worst recovery of both LVEDP and LVDP, along reperfusion; Less recovery of maximum dP/dt, during reperfusion, despite the equivalent LVSP; Reduced basal minimum dP/dt and, subsequently, reduction in the recovery of the aforementioned parameter, regarding reperfusion period; Enhanced gene expression of MHC? (%), consistent with the loss of mechanical performance; Increased incidence of arrhythmic episodes in the reperfusion period (100%, P<0,01). No statistical difference could be seen in regard to the Nox activity. For the first time, we demonstrated that AS treatment during adolescent phase promotes cardiac hypertrophy and gene reprogramming, both persistent during adulthood, besides an increase susceptibility to IRI, through in the larger area of infarct and poor recovery of cardiac electrical and mechanical proprieties, in isolated hearts of adult Wistar rats / De acordo com a OMS, as doen?as isqu?micas do cora??o consistem na maior causa mortis global. Dentre as abordagens terap?uticas, a mais eficaz ? a reperfus?o. A despeito da melhora no progn?stico p?s-infarto, a recupera??o plena da fun??o card?aca dificilmente ? alcan?ada, devido a inj?ria de isquemia/reperfus?o (IIR). Neste contexto, a administra??o de EA em ratos Wistar adultos enaltece a susceptibilidade ? IIR. Ademais, a administra??o de EA em ratos Wistar, ao longo da adolesc?ncia, favorece o desenvolvimento de disfun??es cardiovasculares persistentes durante a fase adulta. Desta forma, objetivou-se, com o presente estudo, analisar os efeitos da sobrecarga cr?nica de propionato de testosterona, ao longo da fase adolescente, na susceptibilidade ? IIR, em ratos Wistar adultos. Para tanto, foram utilizados 24 ratos Wistar machos, divididos em dois grupos: EA (Propionato de testosterona 5 mg kg-1, a partir do 26? dia p?s-natal, 5 vezes por semana/ 5 semanas) e CTL (ve?culo). No 82? dia p?s-natal, os ratos foram submetidos ? eutan?sia para a coleta ?rg?os. Os cora??es isolados foram submetidos ? perfus?o artificial em aparato de Langendorff, e, assim, ao protocolo de isquemia/reperfus?o. As press?es diast?lica final (PDF), sist?lica (PS) e desenvolvida (PD), do ventr?culo esquerdo (VE), e as primeiras derivadas de press?o do VE, m?xima e m?nima (dP/dt m?xima e m?nima, respectivamente), foram mensuradas atrav?s de um bal?o de l?tex intraventricular, conectado a um transdutor de press?o. Atrav?s do eletrocardiograma, foi analisada a susceptibilidade aos epis?dios arr?tmicos. Ao final do protocolo, as ?reas de infarto foram demarcadas e a express?o g?nica das cadeias pesadas de miosina e gliceralde?do-3-fosfato desidrogenase, assim como a atividade enzimas da fam?lia de niconinam?da adenina dinucleot?deo fosfato oxidase (Nox), no ventr?culo esquerdo, foram avaliadas. Em rela??o ao grupo Controle, os cora??es dos animais tratados com EA apresentaram: Hipertrofia, atrav?s do aumento na massa (aumento de 33%, P<0,001) e do ?ndice card?aco (aumento de 37%, P<0,001); aumento significativo da ?rea de infarto (aumento de 54,76%, P<0,05); T?nue recupera??o da PDFVE, assim como da PDVE, durante a reperfus?o; Inferior recupera??o da dP/dt m?xima, ao longo da reperfus?o, a despeito da equivalente recupera??o na PSVE; Reduzida dP/dt m?nima basal e, subsequentemente, redu??o na recupera??o deste par?metro, ao longo da reperfus?o; Aumento significativo da express?o g?nica da MHC? (P<0,01), condizente o preju?zo no desempenho mec?nico; Maior incid?ncia de epis?dios arr?tmicos, ao longo da reperfus?o (aumento de 100%, P<0,01). N?o houve diferen?a em rela??o ?s atividades das Nox. Pela primeira vez, foi demonstrado que a administra??o de EA, ao longo da adolesc?ncia, provoca hipertrofia e reprograma??o g?nica card?aca, persistente durante a fase adulta, al?m de aumentar, significativamente, a susceptibilidade ? IIR, por meio do aumento na ?rea de infarto e piora na recupera??o das propriedades mec?nicas e el?tricas card?acas, em cora??es isolados de ratos Wistar adultos.

Postmenopausal osteoporosis is a disease characterized by bone loss and increased risk of fracture, and represents a significant burden on the Canadian health care system. Current treatments lack the ability to simultaneously address the therapeutic needs for promoting bone formation and inhibiting resorption. Our approach employs a novel conjugate drug in which an anabolic agent (EP4 receptor agonist) is reversibly joined with an anti-resorptive agent (alendronate) through a linker. This allows the bone-targeting ability of alendronate to deliver the EP4 agonist to bone sites, thereby mitigating the side effects associated with systemic administration of the EP4 agonist. This study investigated the in vivo efficacy of this drug in a curative experiment to treat postmenopausal osteoporosis using an ovariectomized rat model. Results showed that conjugate treatment dose-dependently stimulated bone formation and restored ovariectomy-induced bone loss, and conjugation between alendronate and the EP4 agonist was crucial to the drug’s anabolic effect.

Postmenopausal osteoporosis is a disease characterized by bone loss and increased risk of fracture, and represents a significant burden on the Canadian health care system. Current treatments lack the ability to simultaneously address the therapeutic needs for promoting bone formation and inhibiting resorption. Our approach employs a novel conjugate drug in which an anabolic agent (EP4 receptor agonist) is reversibly joined with an anti-resorptive agent (alendronate) through a linker. This allows the bone-targeting ability of alendronate to deliver the EP4 agonist to bone sites, thereby mitigating the side effects associated with systemic administration of the EP4 agonist. This study investigated the in vivo efficacy of this drug in a curative experiment to treat postmenopausal osteoporosis using an ovariectomized rat model. Results showed that conjugate treatment dose-dependently stimulated bone formation and restored ovariectomy-induced bone loss, and conjugation between alendronate and the EP4 agonist was crucial to the drug’s anabolic effect.

The abuse of anabolic androgenic steroids (AAS) is becoming increasingly common and may result in a range of physiological as well as psychological effects such as altered behavior in terms of increased aggression, cognitive dysfunction and addictive behavior. AAS comprise testosterone and its derivatives, of which nandrolone is one of the more common. Previous studies have shown nandrolone-induced effects in male rats on peptide levels within the Substance P (SP) system and the dynorphinergic system; these effects may be linked to some of the reported behavior alterations. The studies presented in this thesis aimed to investigate the mechanisms underlying these peptide alterations and also to further investigate neuropeptidergic effects attributed to nandrolone administration. The results display significant effects on the enzymatic conversion of SP and Dynorphin A into their bioactive metabolites SP(1-7) and Leu-enkephalin-Arg6, respectively, as a result of nandrolone treatment. More profound investigations on the dynorphinergic system displayed effects on the kappa opioid receptor density in various brain regions. There was also a significant increase in the expression of the gene transcript of prodynorphin in the hippocampus, a brain region associated with cognitive processes. In addition, impaired spatial learning and memory in the Morris water maze task following nandrolone administration was encountered. The results provide further understanding regarding neuropeptidergic mechanisms underlying AAS-induced behavioral effects.

17β-nandrolone (17βN) is illegally used in sport and in livestock as a growth promoter.17βN and some of their metabolites have been described as endogenous compounds in some animals, such as adult boars and entire male horses. The aim of this thesis was to identify markers of exogenous administration of 17βN in boars and horses. A method to quantify and identify metabolites of 17βN in the different metabolic fractions has been optimized and validated in boar and horse urine. The method has been applied to urine samples collected after administration of 17βN preparations and to urine samples from non-treated animals to identify endogenous compounds. The following metabolites were identified after the administration of 17βN: 17βN, NorA, NorE, NorEpia, BAB and ABB in boars and 17βN, 17αN, NorEpiA, ABA and ABB in horses. The endogenous compounds detected were: 17βN in boars and horses, and ABA and 17αN only in entire male horses. A chromatographic method by LC/MS/MS has been evaluated to quantify and 17βN sulfate in horse urine and it has been applied to analyze samples from non-treated and treated horses. Concentrations above 30 ng/ml of 17βN sulfate would be evidences of the exogenous administration of 17βN in entire male horses. Preliminary results indicate the capability of GC/C/IRMS analysis to differentiate the endogenous or exogenous origin of 17βN and their metabolites in boars and horses. / La 17β-nandrolona (17βN) s’usa il•legalment en l’esport i com a promotor del creixement en el bestiar. Tant la 17βN com alguns dels seus metabòlits s’han descrit com a compostos endògens en alguns animals, com els porcs adults i els cavalls mascles. L’objectiu de la tesi va ser identificar els marcadors de l’administració exògena de 17βN a porcs i cavalls. Es va optimitzar i validar un mètode basat en la CG/EM per quantificar i identificar els metabòlits de la 17βN en orina de porcs i cavalls en les diferents fraccions metabòliques i es va aplicar a l’anàlisis de mostres procedents d’estudis d’excreció de 17βN i de mostres procedents d’animals no tractats per identificar els compostos endògens. Els metabolits identificats després l’aministració de 17βN van ser: 17βN, NorA, NorE, NorEpiA, BAB i ABB en porcs i 17βN, 17αN, NorEpiA, ABA i ABB en cavalls. Els compostos endògens detectats van ser: 17βN per porcs i cavalls mascles i ABA i 17αN únicament pels cavalls. S’ha avaluat un mètode per CL/EM/EM per quantificar 17βN sulfat en orina de cavall que ha estat aplicat a l’anàlisi de mostres procedents de cavalls no tractats i tractats amb 17βN. Concentracions superiors a 30 ng/ml de 17βN sulfat en orina, seria indicació d’una administració exògena de 17βN. Resultats preliminars obtinguts pel mètode de GC/C/IRMS permeten indicar que mitjançant aquesta tècnica és possible diferenciar l’origen endogen o exogen de 17βN i els seus metabòlits en porcs i en cavalls.